Celltrion set to ramp up pharmacy biz in France with Gifrer acquisition
Celltrion has completed the integration of French health care company Gifrer and plans to strengthen cooperation between the two companies’ sales operations to create greater business synergies, the Korean biopharmaceutical group said Tuesday. According to Celltrion, Chairman Seo Jung-jin visited Gifrer during his trip to France last week and explored ways to combine the French company’s pharmacy…
Celltrion, a Korean biopharmaceutical company, has finalized the integration of French healthcare firm Gifrer and intends to enhance collaboration between the two companies' sales teams. The objective is to capitalize on business synergies by combining Gifrer's extensive pharmacy sales network with Celltrion's offerings. Celltrion's Chairman, Seo Jung-jin, visited Gifrer during a recent trip to France and discussed strategies to merge Gifrer's pharmacy sales network with Celltrion's products, aiming for concrete business outcomes.
Founded in 1912, Gifrer is a prominent pharmacy and healthcare provider with a sales network spanning over 9,000 pharmacies and approximately 800 hospitals throughout France. Celltrion acquired Gifrer's entire stake in May. Despite its rapid expansion in European sales and marketing, focusing on hospitals, medical professionals, and tendering institutions, Celltrion's direct access to pharmacies has been constrained.
The acquisition of Gifrer's pharmacy network is seen as strategically valuable by Celltrion, as it bridges the gap in its direct sales network. This integration facilitates linking prescriptions initiated at hospitals to dispensed medications, thereby expanding Celltrion's reach in the French pharmacy market.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
